Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Shares Outstanding (Weighted Average) (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $696.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 3.58% year-over-year to $696.9 million, compared with a TTM value of $696.9 million through Dec 2025, down 3.58%, and an annual FY2025 reading of $725.4 million, down 7.39% over the prior year.
  • Shares Outstanding (Weighted Average) was $696.9 million for Q4 2025 at Roivant Sciences, up from $680.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $800.6 million in Q4 2023 and bottomed at $630.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $708.5 million, with a median of $706.3 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 202.43% in 2021, then decreased 9.73% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $662.3 million in 2021, then increased by 7.71% to $713.3 million in 2022, then increased by 12.23% to $800.6 million in 2023, then decreased by 9.73% to $722.7 million in 2024, then dropped by 3.58% to $696.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ROIV at $696.9 million in Q4 2025, $680.6 million in Q3 2025, and $680.3 million in Q2 2025.